Post by RV Iyer

Goldman Sachs analysts asked this in a biotech research report. 'Is curing patients a sustainable business model? It further went on to comment "Cures could be bad for business in the long run. While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow." That is the investor mindset for you! #genometherapy #pharmaceuticals #cure #finance #greed #ethicsmatter #goldmansachs #investmentbanking #society #truth #corporatefinance #audit #taxlaws #consulting #strategy #strategicoptions #capitalism #usa #uk #eu #india #big4 #pandemic #covid19 #lobbying #corruption #realitycheck #biotech